Robert Driscoll
Stock Analyst at Wedbush
(1.88)
# 2,947
Out of 4,827 analysts
158
Total ratings
29.93%
Success rate
-9.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $37.64 | +78.00% | 5 | Apr 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.23 | +225.20% | 10 | Mar 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $3.83 | +343.86% | 4 | Mar 21, 2025 | |
| HOWL Werewolf Therapeutics | Reiterates: Outperform | $8 | $0.92 | +767.49% | 2 | Mar 12, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $6.67 | +80.05% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.34 | +404.73% | 6 | Feb 26, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $34 → $36 | $5.68 | +533.80% | 8 | Feb 6, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $17.86 | +191.15% | 9 | Dec 17, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $9.23 | +203.36% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $1.55 | +932.26% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $7.92 | +279.03% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.14 | +1,829.82% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $6.17 | +726.58% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.49 | +919.58% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.70 | +367.84% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.74 | +532.18% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.99 | +225.81% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $1.15 | +1,030.43% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $25.64 | +188.61% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.76 | +355.84% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.32 | +430.30% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.96 | +732.90% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.33 | +2,320.57% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $7.15 | +627.27% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.28 | +22.14% | 4 | May 19, 2020 |
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $37.64
Upside: +78.00%
Zentalis Pharmaceuticals
Mar 28, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.23
Upside: +225.20%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $3.83
Upside: +343.86%
Werewolf Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: $8
Current: $0.92
Upside: +767.49%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $6.67
Upside: +80.05%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.34
Upside: +404.73%
Kura Oncology
Feb 6, 2025
Maintains: Outperform
Price Target: $34 → $36
Current: $5.68
Upside: +533.80%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $17.86
Upside: +191.15%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $9.23
Upside: +203.36%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $1.55
Upside: +932.26%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $7.92
Upside: +279.03%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.14
Upside: +1,829.82%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $6.17
Upside: +726.58%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.49
Upside: +919.58%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.70
Upside: +367.84%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.74
Upside: +532.18%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $3.99
Upside: +225.81%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $1.15
Upside: +1,030.43%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $25.64
Upside: +188.61%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.76
Upside: +355.84%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.32
Upside: +430.30%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.96
Upside: +732.90%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.33
Upside: +2,320.57%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $7.15
Upside: +627.27%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.28
Upside: +22.14%